Please Note :
This website contains information based on the Summary of Product Characteristics (SPC), applicable in the European Union (EU) for/on Jivi (damoctog alfa pegol), Kovaltry (octocog alfa) and Kogenate FS (octocog alfa). It is intended to provide information to an international audience. For countries outside the EU please refer to the applicable local Product Information.
* Please refer to local prescribing information. Not all patients are candidates for 1x weekly dosing. In non-EU countries other FVIII treatments may have previously launched – or are currently available – which also offer 1x weekly dosing.